Attachment
Report Buyer, the online destination for pharmaceutical business intelligence for major industry sectors, has added a new report analysing the global monoclonal antibody market.
“Monoclonal Antibodies Report”, which is available at http://www.reportbuyer.com/
Traditionally, the 'big five' mAbs - Avastin, Herceptin, Rituxan, Humira and Remicade - have dominated the market, cornering almost 80% of sales in 2007. However, authors of the report have identified an 'emerging eight' group of mAbs that will each achieve annual sales of at least $500 million between 2007 and 2013. Together, they will generate a combined increase in annual sales of approximately $11 billion between 2007 and 2013, which represents a larger injection of growth to the mAb segment than from the 'big five' incumbents.
Authors of the report highlight that segmenting the prescription pharmaceutical market by molecule type – small molecule, therapeutic protein, monoclonal antibody and vaccine – reveals different outlooks for the segments, with a particularly stark difference in forecast growth rates between small molecules and monoclonal antibodies.
The small molecule segment will continue to account for the majority of total market sales, but is growing at a slower rate. In contrast, the monoclonal antibody segment will still account for a modest share of total market sales in 2013, but will grow at an impressive CAGR of 10.9% from 2007-13.
The report “Monoclonal Antibodies Report” is available from Report Buyer at: http://www.reportbuyer.com/
Report Buyer product ID: DAT12331
About Report Buyer.
Report Buyer (http://www.reportbuyer.com/
Photo:
http://www.prlog.org/
